It was reported on Monday that Ascentage Pharma (6855.HK), a clinical stage biotechnology company, has received approval from the US Food and Drug Administration (USFDA) for an orphan drug designation for its APG-115, a novel MDM2-p53 inhibitor aimed at treating gastric cancer.
The orphan drug designation provides various development incentives, including a tax credit on expenditures incurred in clinical studies, waiver of the New Drug Application fee, a research grant, and seven years of US market exclusivity should the product hit the market.
The product is an orally administered, selective, small-molecule inhibitor of the MDM2-p53 protein-protein interaction with strong binding affinity to MDM2, aimed at activating tumour suppression activity of p53 by blocking the MDM2-p53 PPI. Preclinical studies were promising.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval